SYRINX has extensive experience of developing new methods using state-of-the-art immunological and cell based techniques for pharmacokinetic (PK) sample analysis.
Our laboratory employs various plate and cellbased technologies, such as TR-FIA, ECL, AlphaLISA, iLITE, TR-FRET, RIA, SPR and ELISA, to assess the immunogenicity of biological drugs and vaccines.
Patient monitoring services are now available!
Concentration/activity analysis and immunogenicity testing using the iLite™ technology platform.
SYRINX is a Contract Research Organization (CRO) offering a large variety of modern immunoassay techniques for the bioanalysis of Biologicals, Biosimilars, Anti-drug antibodies (immunogenicity testing) and Biomarkers.
SYRINX performs bioanalytical studies in compliance with GLP/GCP and also supports GMP analysis for batch release and stability studies. We are continuously striving to fulfill the latest guideline and white paper requirements.
SYRINX Bioanalytics is included in the OECD principles of good laboratory practice (GLP) and EU good manufacturing practice (GMP analytics) monitoring programs.
SYRINX Bioanalytics offers a wide range of state-of-the-art assay techniques ideal for the bioanalysis of biologicals/biosimilars, anti-drug antibodies, vaccines and biomarkers.
CROFinland - Taste of Excellence
A Combination of four Finnish CROs, providing services in Clinical, Statistical & Data Management, Bioanalytical, Pharmacovigilance and Regulatory.
SYRINX will attend the "Nordic Life Science Days 2016" held 14-15 September 2016 in Stockholm, Sweden. Meet us there for partnering!
SYRINX will be presenting at EBF Focus Workshop "Current analysis of immunogenicity – Best Practices and Regulatory Hurdles" held 27-28 September in Lisbon, Portugal. Meet us there!
SYRINX will attend the "EBF 9th Open Meeting: Reaching Utopia - The Kaleidoscope of Bioanalysi held 15-18 November 2016 in Barcelona, Spain.
Immunogenicity analysis - determination of cut points. We use in-house validated MS Excel-templates for statistical evaluation of cut points according to Shankar et al. (Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products: J. Pharm. Biomed. Anal. 2008, 48 (5): 1267-81). More info can be requested by sending E-mail enquiry.
SYRINX is a member of the European Bioanalysis Forum (EBF) together with more than 50 other Pharma and CRO companies.
SYRINX interview is available at Gyros webpage: "In the future, CROs will be in constant communication with their customers and truly become part of the team developing new biologicals".